publication . Article . 2000

A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance

Dermot O'Toole; Michel Ducreux; Gilles Bommelaer; Jean-Louis Wemeau; Olivier Bouch�; France Catus; Jo�lle Blumberg; Philippe Ruszniewski;
  • Published: 15 Feb 2000 Journal: Cancer, volume 88, pages 770-776 (issn: 0008-543X, eissn: 1097-0142, Copyright policy)
  • Publisher: Wiley
BACKGROUND. The somatostatin analogues lanreotide and octreotide have previously been shown to be effective in controlling flushing and diarrhea in patients with carcinoid syndrome. As lanreotide requires injection only every 10 days, compared with twice-daily injections of octreotide, a direct comparison between these two treatments in terms of patient acceptability, patient preference, and efficacy in controlling symptoms was performed in patients with carcinoid syndrome. METHODS. Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study. Half of the patients received octreotide 200 mg subcutaneously twice or thrice d...
free text keywords: Cancer Research, Oncology, Nausea, medicine.symptom, medicine, Gastroenterology, medicine.medical_specialty, Somatostatin, Carcinoid syndrome, medicine.disease, Lanreotide, chemistry.chemical_compound, chemistry, Surgery, Abdominal pain, Crossover study, Prospective cohort study, Octreotide, medicine.drug, business.industry, business, Internal medicine, General surgery
Related Organizations
Download from
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue